脑转移（BrM）是一种癌细胞从身体其他部位转移到大脑的现象，原发性癌症转移至大脑的最常见类型是肺癌、乳腺癌等，BrM可能发生在原发性癌症治疗后数月甚至数年，BrM患者的生存期较短。到目前为止，BrM的免疫逃避机制仍不清楚。 近日，来自美国德克萨斯大学MD安德森癌症中心的Dihua Yu研究团队在Nature Cell Biology上发表题为Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition的文章，发现大脑中的星形胶质细胞可以诱导来源于乳腺癌的BrM细胞中Cdk5高表达，Cdk5通过Irf2bp1-Stat1-importin α-Nlrc5通路抑制MHC-I表达和抗原呈递通路，从而促进免疫逃逸和BrM生长，用Cdk5抑制剂RSV单独处理或与免疫检查点抑制剂联合处理可以显著抑制BrM。 研究人员首先比较了21个人类BrM和对应的原发性乳腺癌中Cdk基因的表达，发现在BrM中Cdk5是上调最

Oct. 21, 2024 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the initiation of an artificial intelligence (AI)-focused collaboration with Tempus AI, Inc. (Nasdaq: TEM), a technology company leading the adoption of artificial intelligence to advance precision medicine and patient care. The strategic collaboration will provide Avacta access to Tempus’

Detailed safety and efficacy results to be presented Data show potential of CNP-104 to slow disease progression as demonstrated by statistically significant decrease in liver stiffness compared with placebo Oct. 21, 2024 -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to induce antigen-specific tolerance for autoimmune diseases, today announced it will present detailed safety and efficacy results from the Phase 2a stu

-- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- Oct. 21, 2024 -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, tod

Oct. 21, 2024 -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, in patients with previously treated, metastatic pancreatic ductal adenocarcinoma (PDAC). RASolute 302 is a global, randomized, open-label Phase 3 study designed to evaluate the safet

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and proof-of-concept data to be presented at a scientific meeting in 1H 2025 Oct. 23, 2024 -- Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, today announced that the first study participant has been dosed i

2024年10月21日，德烽药业（“Adcentrx”）宣布，美国食品药品监督管理局（FDA）批准了ADRX-0405的新药临床试验（IND）申请，用于治疗选择性晚期实体肿瘤。 ADRX-0405是一款靶向六跨膜前列腺上皮抗原1（STEAP1）的抗体偶联药物（ADC），具有同类首创药物的潜力。该试验预计在2024年第四季度招募首例受试者，并于2025年第四季度公布初步数据。 ADRX-0405由靶向STEAP1的人源化IgG1抗体组成，具有高度稳定的药物-抗体比（DAR8）。临床前研究显示，ADRX-0405具有良好的药代动力学和安全性特征，同时在多种肿瘤模型中展现出显著的疗效。 本次获批的1a/b期临床试验是一项开放标签，多中心，非随机性的剂量递增和剂量扩展研究，旨在包括转移性去势抵抗性前列腺癌受试者在内的晚期实体瘤患者中，评估ADRX-0405的安全性和耐受性，并确定其最佳剂量。 STEAP 家族成员蛋白分别为STEAP1、STEAP2、STEAP3 和STEAP4。STEAP1主要在前列腺细胞中表达，而在肝、肺、胃、脾和胰腺等组织细胞中低表达或几乎不表达；在前列腺中，ST

Data highlight potential of FLT201 to set new standard of care for Gaucher disease Dramatic and durable reductions observed in lyso-Gb1, an established biomarker of clinical response, in patients with persistently high levels despite years of prior treatment on currently approved therapies Substantial improvements in bone marrow burden demonstrate FLT201 penetrating deeper tissues that currently approved therapies poorly address Favorable safety and tolerability continue to be seen in all patien

10月22日上午，北京经开区与上海复星医药（集团）股份有限公司（以下简称“复星医药”）签署战略合作框架协议，开启政企深度务实合作新里程。北京经开区工委书记张强，工委副书记、管委会主任孔磊与复星医药董事长吴以芳一行举行工作会谈，并完成合作协议的签署。 张强代表工委管委会对吴以芳一行表示欢迎，并介绍了经开区最新产业发展情况。他说，当前，北京经开区正深入贯彻落实习近平总书记对国家级经济技术开发区工作重要指示精神，紧抓生物医药产业发展机遇，不断集聚先进生产要素，加快规划建设医药创新公园（BioPark），全力打造国际医药创新资源的引领区、集聚区。复星医药是植根中国、创新驱动的全球化医药健康产业集团，此次双方签署战略合作协议恰逢其时，将为经开区生物医药产业发展注入新动力。未来，双方将立足各自优势能力和资源禀赋，围绕药械产品的研发、生产、销售全产业链条开展务实合作，携手培育一批示范性项目，为首都医药健康产业发展添势赋能。经开区将一如既往主动靠前服务，持续优化国际一流营商环境，全力支持复星医药加快发展成为生物医药先进智造标杆企业。 吴以芳高度赞赏经开区生物医药产业的聚集态势，表示对双方合作充满信

Oct. 22, 2024 -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). Based on initial pharmacokinetic results, two additional dosing cohorts with twice daily (BID) oral dosing of ONCT-534 had been incorporated in the Phase 1/2 study ONCT-534-101 (NCT05917470). Overall, fifteen patients received ONCT-534 once